Selenium infusions in late-stage cancer show measurable blood levels, raising drug development questions

Researchers tracked how the body processes high-dose selenium when administered intravenously to terminal cancer patients, mapping systemic exposure and metabolite formation. The findings could inform whether selenium or related compounds warrant further development as cancer treatments and how to optimize dosing strategies.

Originaltitel: Intravenous Infusion of High Dose Selenite in End-Stage Cancer Patients: Analysis of Systemic Exposure to Selenite and Seleno-Metabolites